Join our panel of experts as they discuss important attributes associated with choosing the right partners, including flexibility and scalability, allogeneic donor recruitment, the ability to leverage healthcare relationships to access more patients, and providing different human-derived clinical starting material.
As the clinical commercial approval of many novel therapies come to market, the need for quality clinical partners has never been higher. It can mean the success or failure of scalability.
During this webinar, the panel will discuss how choosing the right partner can assist clients through the process of transitioning therapies from R&D through clinical approval and into commercialization, with the end goals always in mind.
The panel will also discuss how clients with existing therapies can scale faster through the right partnerships.
“We want to help these incredible therapies get to market faster and reduce the cost in the process. Additionally, by utilizing these therapies at earlier stages of disease, we may significantly improve their effectiveness and ultimately curative potential.” – Dr Andrew Branagan, Medical Director, StemExpress.
WHAT TO EXPECT
This 60-minute session will feature a short presentation with a session dedicated to an interactive panel discussion where you will be able to ask your questions.
Part 1: The panel addresses key challenges associated with scaling clinical and gene therapies:
Enhanced allogeneic donor recruitment – find the right donors
Flexibility in human-derived clinical starting material – whole blood, apheresis, cryopreserved
Leverage healthcare partnerships to access patients that can benefit from your therapy
Part 2: The panel answers audience questions with an interactive Q&A.
MEET THE PANEL
Dr Gregory Graves
Chief Medical Officer
Founder & CEO
BRL C> Consulting
Moderator: Georgi Makin
This content is brought to you in partnership with Phacilitate and StemExpress, who are independent but joint controllers. You may receive follow up communications from Phacilitate and StemExpress with information directly related to this content, and you will be able to opt out from being contacted by using the unsubscribe links in these emails.